Cited by 146Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study

Lin, Chia-Chi, Shih, Jin-Yuan, Yu, Chong-Jen, Ho, Chao-Chi, Liao, Wei-Yu, Lee, Jih-Hsing, Tsai, Tzu-Hsiu, Su, Kang-Yi, Hsieh, Min-Shu, Chang, Yih-Leong, Bai, Ya-Ying, Huang, Derek De-Rui, Thress, Kenneth S, Yang, James Chih-Hsin·2018·The Lancet Respiratory Medicine

DOI 10.1016/s2213-2600(17)30480-0

Open this paper in CoChat — free account

Abstract

Background Osimertinib is approved for the treatment of non-small-cell lung cancer in patients who develop the EGFR Thr790Met mutation after treatment with epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs). We assessed outcomes in patients with non-small-cell lung cancer and the EGFR Thr790Met mutation who were treated with osimertinib, a third-generation EGFR TKI, after previous treatment failure with one or more other EGFR TKIs.Methods Eligible patients had been enrolled at one centre in the AURA study, had shown resistance to a previous EGFR TKI, and had EGFR-activating mutations and acquired Thr790Met mutation detectable in tumour tissue or plasma. Patients took 20-240 mg osimertinib per day until disease progression or development of intolerable side-effects. Plasma samples were collected every 6 weeks and tumour tissue biopsy was done at study entry and was optional after disease progression. We tested samples for resistance mechanisms, including EGFR-activating, Thr790Met, and Cys797Ser mutations, and assessed associations with overall survival, progression-free survival, and survival after disease progression.Findings Of 71 patients enrolled in AURA, 53 were eligible for this analysis. Median progression-free survival was 11·1 months (95% CI 8·4-13·9) and overall survival was 16·9 months (11·7-29·1). 47 patients had disease progression. Median overall survival after osimertinib progression was 5·4 months (95% CI 4·1-10·0). Plasma samples were available for 40 patients after disease progression. 12 (30%) of these had the Thr790Met mutation (four of whom also had Cys797Ser mutations). Patients without detectable EGFR-activating mutations in plasma before treatment had the best overall and post-progression survival (22·4 months, 95% CI 15·6-not reached, and 10·8 months, 7·2-not reached, respectively). Loss of the Thr790Met mutation but presence of EGFR-activating mutations in plasma were associated with the shortest progression-free survival (median 2·6 months, 95% CI 1·3-not reached). In 22 post-progression tumour samples, we found one squamous cell and two small-cell transformations. We detected Thr790Met in nine (50%) of 18 samples, Cys797Ser in two (17%) of 12, cMET amplification in five (50%) of ten, BRAF mutation in one (8%) of 13, and KRAS mutation in one (8%) of 13.Interpretation Heterogeneous resistance mechanisms developed in patients receiving osimertinib. Differences in resistance mechanisms might dictate future development strategies for osimertinib in clinical trials.Funding AstraZeneca, Taiwan Ministry of Science and Technology.

Integrity signals

Registry

Crossref · 10.1016/s2213-2600(17)30480-0

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
Jänne, P. A., Yang, J. C.-H., Kim, D.-W., Planchard, D., Ohe, Y., Ramalingam, S. S., Ahn, M.-J., Kim, S.-W., Su, W.-C., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411817 · Cited by 2,116
Self-citation
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
Thress, K. S., Paweletz, C. P., Felip, E., Cho, B. C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3854 · Cited by 1,589
Self-citation
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer
Oxnard, G. R., Thress, K. S., Alden, R. S., Lawrance, R., Paweletz, C. P., Cantarini, M., Yang, J. C.-H., Barrett, J. C., & Jänne, P. A. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.7162 · Cited by 850
Self-citation
Noninvasive Detection of Response and Resistance in EGFR -Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA
Oxnard, G. R., Paweletz, C. P., Kuang, Y., Mach, S. L., O'Connell, A., Messineo, M. M., Luke, J. J., Butaney, M., Kirschmeier, P., Jackman, D. M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2482 · Cited by 786
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
Goss, G. D., Tsai, C., Shepherd, F. A., Bazhenova, L. A., Lee, J. S., Chang, G., Crinò, L., Satouchi, M., Chu, Q. S.-C., Hida, T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30508-3 · Cited by 654
Self-citation
Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component
Yang, J. C.-H., Ahn, M.-J., Kim, D.-W., Ramalingam, S. S., Sequist, L. V., Su, W.-C., Kim, S.-W., Kim, J.-H., Planchard, D., Felip, E., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.3223 · Cited by 571
Self-citation
Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer
Ramalingam, S. S., Yang, J. C., Lee, C. K., Kurata, T., Kim, D., John, T., Nogami, N., Ohe, Y., Mann, H., Rukazenkov, Y., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.7576 · Cited by 563
Self-citation

Show all 23 references

Sorted by citations

Items 101–146 of 146

Comprehensive molecular and clinical insights into non-small cell lung cancer transformation to small cell lung cancer with an illustrative case report
Tomić, K., Krpina, K., Batičić, L., Samaržija, M., & Vranić, S. (2024) · Journal of drug targeting · doi:10.1080/1061186x.2024.2332733 · Cited by 8
Multiomics and Single-Cell Insights Reveal a Lysophosphatidic Acid–Mediated Resistant Mechanism to Third-generation EGFR-TKI in Non–Small Cell Lung Cancer
Gao, R., Lou, N., Yang, S., Yang, M., Fan, G., Dai, L., Tang, L. M., Yao, J., Han, X., & Shi, Y. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0993 · Cited by 8
Squamous cell carcinoma transformation after acquired resistance to osimertinib in a patient with lung adenocarcinoma harboring uncommon EGFR mutation
Chiang, C., Yeh, Y., Chou, T., & Chiu, C. (2020) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2019.12.017 · Cited by 8
Absence of copy number gain ofEGFR: A possible predictive marker of long‐term response to afatinib
Nakamura, T., Sato, A., Nakashima, C., Abe, T., Iwanaga, K., Umeguchi, H., Kawaguchi, A., & Sueoka‐Aragane, N. (2022) · Cancer Science · doi:10.1111/cas.15655 · Cited by 8
Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation
Watanabe, K., Saito, R., Miyauchi, E., Nagashima, H., Nakamura, A., Sugawara, S., Tanaka, N., Terasaki, H., Fukuhara, T., & Maemondo, M. (2023) · Cancers · doi:10.3390/cancers15174231 · Cited by 8
Genetic alterations in epidermal growth factor receptor‑tyrosine kinase inhibitor‑na�ve non‑small cell lung carcinoma
Yamaura, T., Muto, S., Mine, H., Takagi, H., Watanabe, M., Ozaki, Y., Inoue, T., Fukuhara, M., Okabe, N., Matsumura, Y., et al. (2020) · Oncology Letters · doi:10.3892/ol.2020.11524 · Cited by 8
The expanding capability and clinical relevance of molecular diagnostic technology to identify and evaluate EGFR mutations in advanced/metastatic NSCLC
Shah, P. S., Sands, J. M., & Normanno, N. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.08.001 · Cited by 8
Liquid biopsy in the management of advanced lung cancer: Implementation and practical aspects
Fernandes, G., Rodrigues, A., Matos, C., Barata, F. J., Cirnes, L., Ferreira, L., Lopes, J. A., Felizardo, M., Fidalgo, P., Brito, U., et al. (2023) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2023.100725 · Cited by 7
Prospective Observational Study of Treatment Resistance-related Gene Screening Using Plasma Circulating Tumor DNA in Third-generation EGFR-TKI Osimertinib Therapy (Elucidator)
Tamiya, A., Isa, S., Taniguchi, Y., Nakagawa, H., Atagi, S., Ando, M., & Koh, Y. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.05.023 · Cited by 7
Integrated histological and molecular analyses of rebiopsy samples at osimertinib progression improve post-progression survivals: A single-center retrospective study
Cheng, J., Yao, Y., Gao, Y.-E., Zhang, S., Chen, H., Wang, Z., Yan, H., Zhou, Q. H., Tu, H., Zhang, X., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.10.010 · Cited by 7
Self-citation
Curative effectiveness and safety of osimertinib in the treatment for non-small-cell lung cancer: a meta-analysis of the experimental evidence
Chen, P., Chen, F., Lei, J., & Zhou, B. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s182077 · Cited by 7
Clinical study of apatinib combined with EGFR‐TKI in the treatment of chronic progression after EGFR‐TKI treatment in non‐small cell lung cancer (ChiCTR1800019185)
Li, X., Liu, M., Zhang, H., Liu, H., & Chen, J. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13303 · Cited by 7
Resistance to EGFR Inhibitors: Fitness, Competition, and Diversity
Le, X. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.01.006 · Cited by 7
EGFR ‐plasma mutations in prognosis for non‐small cell lung cancer treated with EGFR TKIs : A meta‐analysis
Phan, T. T., Tran, V. T., Tran, B., Ho, T. T., Pho, S. P., Le, A. T., Le-Thuong, V., Nguyen, H. T., & Nguyen, S. T. (2021) · Cancer Reports · doi:10.1002/cnr2.1544 · Cited by 6
Dynamics of disease progression during treatment with Osimertinib in patients with EGFR T790M‐positive non‐small cell lung cancer
Kim, H. S., Lim, K. Y., Lee, S. D., Kim, H. Y., Lee, Y., & Han, J. (2023) · Cancer Medicine · doi:10.1002/cam4.5926 · Cited by 6
The combination of osimertinib with Raf inhibitor overcomes osimertinib resistance induced by KRAS amplification in EGFR-mutated lung cancer cells
Lee, T., Kang, H.-M., Kim, S. Y., Kim, H.-R., & Kim, C. H. (2023) · Experimental Cell Research · doi:10.1016/j.yexcr.2023.113722 · Cited by 6
The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy
Cheng, W., Hsia, T., Tu, C., & Chen, H.-J. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s279540 · Cited by 6
Combined analysis of circulating tumor DNA and tumor tissue to overcome osimertinib resistance (OSIRIS); the second line osimertinib cohort
van der Wel, T. J. W. T., Jebbink, M., van den Broek, D. A., Steinbusch, L. C., Theelen, W. S. M. E., Ruiter, G., Buikhuisen, W. A., Burgers, J. A., Baas, P., Vermeulen, M., et al. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107972 · Cited by 5
Deciphering the Impact of Rare Missense Variants in EGFR-TKI-Resistant Non-Small-Cell Lung Cancer through Whole Exome Sequencing: A Computational Approach
Balasundaram, A., & Doss, C. G. P. (2024) · ACS Omega · doi:10.1021/acsomega.3c10229 · Cited by 5
MCAM interacts with integrin β1 to promote EGFR-TKI resistance in lung adenocarcinoma through the JAK3 signalling pathway
Zhang, S., Chen, Y., Li, C., Zhao, J., Jiao, M., Zhang, M., Ma, C., Wang, A., Li, J., Zeng, Y., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06874-9 · Cited by 4
Phase Ib Study of Osimertinib Plus Ramucirumab in Japanese Lung Cancer Patients With EGFR Mutation
Akamatsu, H., Ozawa, Y., Oyanagi, J., Fujimoto, D., Hata, A., Katakami, N., Tomii, K., Murakami, E., Sugimoto, T., Shimokawa, T., et al. (2021) · Anticancer Research · doi:10.21873/anticanres.14844 · Cited by 4
Antiangiogenesis May Not Be a Universal Booster of EGFR Tyrosine Kinase Inhibitors
Wu, T., & Lin, C. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.06.012 · Cited by 4
Self-citation
DNA shedding in non-small-cell lung cancer: useful to assess?
Suda, K. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30479-4 · Cited by 3
Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLC
Tung, P., Chiu, T.-H., Huang, A. C., Ju, J., Huang, C., Wang, C., Ko, H., Chung, F., Hsu, P., Fang, Y., et al. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231222604 · Cited by 2
Molecular Mechanisms of Acquired Therapeutic Resistance to Tyrosine Kinase Targeted Therapy
Fu, L., & Luo, M. (2025) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-031-93894-8_8 · Cited by 2
Case report: Sustained remission after combined sintilimab, anti-VEGF therapy, and chemotherapy in a patient with non-small cell lung cancer harboring acquired EGFR 19Del/T790M/cis-C797S mutation resistance
He, W., Tong, L., Yang, W. J., Yuan, Y., Li, Y., & Tang, W. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1298389 · Cited by 2
ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
Soo, R. A., Dafni, U. G., Han, J., Cho, B. C., Nadal, E., Yeo, C. M., Carcereny, E., de Castro, J., González, M. Á. S., Coate, L. E., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0932 · Cited by 2
PD-L1 regulates c-MET phosphorylation and contributes to MET-dependent resistance to osimertinib in EGFR-mutant NSCLC
Hsu, C.-C., Huang, D. D.-R., Hsu, W., Hsieh, M., Lin, F., Tai, P.-C., Chou, S.-Y., Tsai, H.-H., Tseng, C., Liao, B.-C., et al. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01181-3 · Cited by 2
Self-citation
Circulating tumour DNA genomics in EGFR-mutant lung adenocarcinoma
Rosell, R., & Karachaliou, N. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30292-3 · Cited by 2
The impact of EGFR T790M mutation status following the development of Osimertinib resistance on the efficacy of Osimertinib in non‐small cell lung cancer: A meta‐analysis
Guo, L., Zhou, G., Huang, M., Tang, K., Xu, J., & Chen, J. (2024) · The Clinical Respiratory Journal · doi:10.1111/crj.13748 · Cited by 2
Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC
Liao, B.-C., Hsu, W., Lee, J., Yang, C., Tsai, T.-H., Liao, W., Ho, C., Lin, C., Shih, J., Yu, C., et al. (2020) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2020.100099 · Cited by 2
Self-citation
Elevated Exosome-derived Mirnas Predict Osimertinib Resistance in Non-small Cell Lung CancerPreprint
Li, X., Chen, C., Wang, Z., Liu, J., Sun, W., Shen, K., Yan-ling, L., Zhu, S., Zhan, P., Lv, T., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-122187/v1 · Cited by 2
Intratumoral Resident Microbes Directly Participate in Resistance to EGFR-TKI Targeted Drug Therapy through Metabolism in NSCLCPreprint
Wang, H., Zhang, J., Zhang, J., Hou, W., Zhou, J., Li, M., Liu, X., Li, Y., Fu, F., Tian, P., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.12.642829 · Cited by 2
Anlotinib Plus Osimertinib in Osimertinib‐Resistant Nonsquamous Nonsmall Cell Lung Cancer With Gradual Progression: A Retrospective Study
Yu, H., Liu, M., Li, B.-X., Zhang, H., Zhang, Z., Wang, Y., Liu, J., Li, X., Li, Y., Wei, S., et al. (2025) · Thoracic Cancer · doi:10.1111/1759-7714.70071 · Cited by 1
Germ-line exon 21 EGFR V831H mutation in advanced NSCLC resistance to almonertinib: a case report
Cai, D., Jian, L., Zhu, Y., & Wang, Y. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1758636 · Cited by 1
Osimertinib versus afatinib in patients with T790M-positive, non-small-cell lung cancer and multiple central nervous system metastases after failure of initial EGFR-TKI treatmentPreprint
Chen, W. K., Hua, X., Yu, W., Liu, J., Li, X., & Han, G. (2019) · Research Square · doi:10.21203/rs.2.15588/v1
Osimertinib
(2018) · Reactions Weekly · doi:10.1007/s40278-018-42463-9
An exploration of the clinical progression models of osimertinib in the treatment of advanced EGFR-mutant non-small cell lung cancer
Shi, Y., Jiang, Y., Pan, B., Wang, Z., Li, H., Ma, Y., Liu, Y., He, K., Wang, Z., Lu, J., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-315
A Meta-analysis of Randomised Controlled Trials Comparing Combination Therapy as Second-line Treatment With Monotherapy in Advanced Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutation
Zhao, K.-X., Zhang, Y., Zheng, L. Z., Pan, Y.-F., & He, Z.-H. (2023) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000001047
Is Real-World Evidence on Acquired Resistance to Osimertinib Relevant Clinically?
Lee, J. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.11.003
Self-citation
Long-term survival with pemetrexed-based chemotherapy in a patient with metastatic lung adenocarcinoma of unclear primary origin harboring MTHFR C677T(T/T) mutation: a case report
Yu, Y., Li, N., & Wang, J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2024.1435357
Compréhension des étapes précoces de la résistance adaptative aux inhibiteurs de tyrosine kinase de l'EGFR dans les cancers bronchiques
Figarol, S. (2020) · theses.fr (ABES) · doi:10.70675/9b097a88z7be2z4f00z913fze60d534fa601
Une nouvelle stratégie thérapeutique pour prolonger la réponse du cancer bronchique aux inhibiteurs d’EGFR en prévenant l’émergence des cellules résistantes
Brunet, L. (2021) · theses.fr (ABES) · doi:10.70675/a4e459eez153dz4ec7z924fza1c1c6e4fdd6
Identification and Validation of the Ferroptosis‐Related Gene SLC2A1 as a Novel Prognostic Biomarker for Osimertinib Resistance in LUAD
Zhang, L., Jia, E., Wang, H., Chang, J., Li, L., Zhang, H., Liang, X., & Zhang, H. (2026) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1155/jcpt/3169792
Navigating Uncharted Waters: Steering the Course and Confronting Challenges of Brain Metastases in EGFR-Mutant Non-Small Cell Lung Cancer
Garcez, D., Rodrigues, A., Travancinha, C., Pantarotto, M., Costa, P., Araújo, A., Rachadell, J., Ramalho-Carvalho, J., Figueiredo, A. A., Sequeira, T. C. A., et al. (2026) · Cancers · doi:10.3390/cancers18162647
Machine-Learning-Guided Identification of Potent Osimertinib Analogues Targeting the EGFR Triple Mutant
Ahamad, S., Kuldeep, J., Ahmad, S., & Gupta, D. K. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18111409

Authors: Lin, C.-C., Shih, J.-Y., Yu, C.-J., Ho, C.-C., Liao, W.-Y., Lee, J.-H., Tsai, T.-H., Su, K.-Y., Hsieh, M.-S., Chang, Y.-L., Bai, Y.-Y., Huang, D. D.-R., Thress, K. S., & Yang, J. C.-H.
Affiliations: National Taiwan University Hospital (TW)
National Taiwan University (TW)
AstraZeneca (United States) (US)
Corresponding author: Yang, James Chih-Hsin
ORCID: Lin, Chia-Chi
Shih, Jin-Yuan
Yu, Chong-Jen
Ho, Chao-Chi
Liao, Wei-Yu
Tsai, Tzu-Hsiu
Su, Kang-Yi
Hsieh, Min-Shu
Chang, Yih-Leong
Huang, Derek De-Rui
Yang, James Chih-Hsin
Venue: The Lancet Respiratory Medicine
Publisher: Elsevier BV
Published: 2018-02
Volume: 6
Issue: 2
Pages: 107-116
ISSN: 2213-2600 (ISSN-L)
DOI: 10.1016/s2213-2600(17)30480-0
OpenAlex: W2772237551
Cited by: 145
References: 23
Citations by year: 2026: 3 · 2025: 8 · 2024: 13 · 2023: 16 · 2022: 15 · 2021: 29 · 2020: 20 · 2019: 24 · 2018: 16
FWCI: 13.80
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet Respiratory Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: AstraZeneca
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: non-small cell lung cancer, osimertinib, acquired resistance, EGFR tyrosine kinase inhibitors, EGFR activating mutations, plasma biomarkers, resistance mechanisms, progression-free survival, overall survival, post-progression survival, third-generation EGFR-TKI
MeSH terms: Acrylamides, Adult, Aged, Aged, 80 and over, Aniline Compounds, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Indoles, Lung Neoplasms, Male, Middle Aged, Mutation, Piperazines, Pyrimidines, Retrospective Studies, Genomics, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks